Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Montijo – page 43

673 clinical trials in Montijo, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Montijo at a glance
673
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

673 trials in Montijo

Open in trial search

Alopecia areata

Not recruiting

Study on the Safety and Effectiveness of Upadacitinib for Adults and Adolescents with Severe Alopecia Areata

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Myelofibrosis

Not recruiting

Study of Imetelstat Compared to Drug Combination for Treating Intermediate-2 or High-Risk Myelofibrosis in Patients Not Responding to JAK-Inhibitor Treatment

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Alkylating agents
  • Sponsor:Geron Corp.

Study on the Effectiveness and Safety of Litifilimab for Patients with Active Subacute or Chronic Cutaneous Lupus Erythematosus Resistant to Antimalarial Therapy

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Litifilimab
  • Sponsor:Biogen Idec Research Limited

Study of V940 and Pembrolizumab for Patients with Resected Stage II, IIIA, IIIB Non-Small Cell Lung Cancer

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Study of OP-1250 for Treating Advanced or Metastatic ER+, HER2- Breast Cancer in Patients After Endocrine and CDK4/6 Inhibitor Therapy

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Olema Pharmaceuticals Inc.

Study on Bomedemstat for Patients with Essential Thrombocythemia Not Responding to or Intolerant of Hydroxyurea, Comparing with a Drug Combination

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Bomedemstat
  • Sponsor:Merck Sharp & Dohme LLC

Study comparing giredestrant plus palbociclib versus letrozole plus palbociclib in patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Giredestrant
  • Sponsor:F. Hoffmann-La Roche AG

Study of Niraparib, Abiraterone Acetate, and Prednisone for Patients with Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Janssen Cilag International

Study of Niraparib, Abiraterone Acetate, and Prednisone for Patients with Metastatic Prostate Cancer

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Janssen Cilag International

Study on TAR-200 and Cetrelimab for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Received BCG Treatment

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Cetrelimab
  • Sponsor:Janssen Cilag International

Study on the Safety and Effectiveness of Epcoritamab with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Erosive oesophagitis

Not recruiting

Study on Esomeprazole Magnesium for Maintaining Healing of Erosive Esophagitis in Children Aged 1 to 11 Years

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Esomeprazole Magnesium
  • Sponsor:AstraZeneca AB

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Montijo

What the registry says about research in the country

01 Cardiovascular Diseases

Montijo hosts a focused research effort on cardiovascular diseases, with two active recruiting trials at a single site led by a local investigator.

  • Evaluation of zilebesiran in patients with uncontrolled hypertension and established or high‑risk cardiovascular disease
  • Assessment of the antibody combination REGN7508 and REGN9933 for preventing ischemic stroke and systemic embolism in atrial fibrillation patients
  • Investigation of major bleeding risk associated with the REGN antibody therapy
  • Inclusion of participants with atrial fibrillation, established cardiovascular disease, high cardiovascular risk and hypertension

These studies aim to improve outcomes by testing novel therapies and safety profiles, positioning Montijo as a niche hub for cardiovascular innovation in Portugal.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.